FR2988611B1 - Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations - Google Patents

Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations

Info

Publication number
FR2988611B1
FR2988611B1 FR1257221A FR1257221A FR2988611B1 FR 2988611 B1 FR2988611 B1 FR 2988611B1 FR 1257221 A FR1257221 A FR 1257221A FR 1257221 A FR1257221 A FR 1257221A FR 2988611 B1 FR2988611 B1 FR 2988611B1
Authority
FR
France
Prior art keywords
progestative
micronized
composition
polymer carrying
pyrrolidone group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1257221A
Other languages
English (en)
Other versions
FR2988611A1 (fr
Inventor
Celine Gnakamene
Rachel Levy-Toledano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effikal International ISA
Original Assignee
Effik SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effik SA filed Critical Effik SA
Priority to FR1257221A priority Critical patent/FR2988611B1/fr
Priority to PCT/EP2013/056840 priority patent/WO2013144356A1/fr
Publication of FR2988611A1 publication Critical patent/FR2988611A1/fr
Application granted granted Critical
Publication of FR2988611B1 publication Critical patent/FR2988611B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR1257221A 2012-03-30 2012-07-25 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations Expired - Fee Related FR2988611B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1257221A FR2988611B1 (fr) 2012-03-30 2012-07-25 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
PCT/EP2013/056840 WO2013144356A1 (fr) 2012-03-30 2013-03-29 Stéroïde, en particulier un progestatif, co-micronisé avec un polymère portant le groupe pyrrolidone, compositions et utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1252906A FR2988610B1 (fr) 2012-03-30 2012-03-30 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
FR1257221A FR2988611B1 (fr) 2012-03-30 2012-07-25 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations

Publications (2)

Publication Number Publication Date
FR2988611A1 FR2988611A1 (fr) 2013-10-04
FR2988611B1 true FR2988611B1 (fr) 2014-10-31

Family

ID=46852284

Family Applications (2)

Application Number Title Priority Date Filing Date
FR1252906A Expired - Fee Related FR2988610B1 (fr) 2012-03-30 2012-03-30 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
FR1257221A Expired - Fee Related FR2988611B1 (fr) 2012-03-30 2012-07-25 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR1252906A Expired - Fee Related FR2988610B1 (fr) 2012-03-30 2012-03-30 Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations

Country Status (2)

Country Link
FR (2) FR2988610B1 (fr)
WO (1) WO2013144356A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103877059A (zh) * 2014-03-26 2014-06-25 邵娜 一种醋酸诺美孕酮片及其制备工艺
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821555B1 (fr) * 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations

Also Published As

Publication number Publication date
WO2013144356A1 (fr) 2013-10-03
FR2988610A1 (fr) 2013-10-04
FR2988611A1 (fr) 2013-10-04
FR2988610B1 (fr) 2014-10-31

Similar Documents

Publication Publication Date Title
FR2988611B1 (fr) Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
EP2812708A4 (fr) Dispositifs à nano-entonnoirs fluidiques, procédés associés, systèmes de fabrication et d'analyse
JP2014508326A5 (fr)
EP2672273A4 (fr) Puce d'inspection, et ensemble puce d'inspection comportant la puce d'inspection
BR112015008210A2 (pt) métodos e sistemas de concentrador de oxigênio dual.
BR112014033075A2 (pt) dispositivo de gaxeta, e, turbomáquina.
CO6960553A2 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
EP2841709A4 (fr) Pale à élément amortisseur flottant libérable par rupture
HK1214285A1 (zh) 聚苯胺膜、其用途及其方法
HK1205166A1 (en) Polymer, composition and use
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
PL2650310T3 (pl) Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
JP2013541099A5 (fr)
ZA201408712B (en) Fibre-reactive dyes, their preparation and their use
CL2014002083A1 (es) Tionocarbamatos y procesos de preparacion.
SG2013095823A (en) Novel acryl monomer, polymer and resist composition comprising the same
PT3063228T (pt) Corantes dispersos, sua preparação e sua utilização
GB2517634B (en) Connection arrangements, pivots and mechanisms
JP2014113267A5 (fr)
EP2810684A4 (fr) Embase et cathéter à embase
HK1209026A1 (en) Vesicular formulations, kits and uses
HK1213978A1 (zh) 流感病毒和 型糖尿病
FR2992145B1 (fr) Rhizotron et utilisations de celui-ci.

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: EFFIK INTERNATIONAL, BE

Effective date: 20140602

ST Notification of lapse

Effective date: 20160331